



MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference

03/28/22

DANBURY, Conn., March 28, 2022 (GLOBE NEWSWIRE) -- **MannKind Corporation (Nasdaq: MNKD)**, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

The Company's webcast presentation will be available for viewing at 11:00am ET on Monday, April 4, 2022, on the Company's website at or <https://wsw.com/webcast/lytham4/mnkd/2026590>. The webcast will also be archived and available for replay.

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at www.lythampartners.com/spring2022invreg.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company's partner, Biomm SA. MannKind was established in 1991, and is located in Danbury, Conn., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

Company Contact:

Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com



Source: MannKind